Image source: © 2025 Krish Capital Pty.Ltd

Highlights
• GBP130 million R&D centre under construction in Weybridge, Surrey
• Facility aims to advance global oral health research and innovation
• Site received BREEAM® Outstanding rating at Phase 1 design stage

Haleon (LSE/NYSE: HLN) has broken ground on its new GBP130 million Global Oral Health Innovation Centre in Weybridge, Surrey. The project marks a significant step in the company’s expansion of its oral health research and development infrastructure. Once completed, the centre will act as a hub for scientific collaboration and product development within Haleon’s global oral health portfolio.

The facility will integrate research, digital innovation, commercial planning, and supply chain functions. It will also feature a digital immersive room to facilitate real-time collaboration with Haleon’s manufacturing site in Levice. The building’s atrium is designed to serve as a central space for co-creation and interdisciplinary teamwork.

The site has achieved a BREEAM® Outstanding rating at the Phase 1 design stage, underscoring its sustainability credentials. BREEAM (Building Research Establishment Environmental Assessment Method) is a recognized standard for sustainable building practices in the UK.

Haleon develops and markets consumer health products across six categories: oral health, vitamins and supplements, pain relief, respiratory health, digestive health, and skin health. Its product lines include brands such as Sensodyne, parodontax, Polident, Panadol, Advil, and Voltaren. The company operates globally and maintains listings on both the London Stock Exchange and the New York Stock Exchange under the ticker HLN.